Elias Jabbour, MD
Enriched profileProfessor, Department of Leukemia, Division of Cancer Medicine; Section Chief, Acute Lymphocytic Leukemia (since 2015) · The University of Texas MD Anderson Cancer Center
Elias Jabbour is Professor, Department of Leukemia, Division of Cancer Medicine; Section Chief, Acute Lymphocytic Leukemia (since 2015) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,365 publications with 56,927 citations (h-index 115); ClinicalTrials.gov lists 38 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Elias Jabbour, M.D., is Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 2,365 publications with 56,927 citations (h-index 115), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 38 registered clinical trials, industry payments reported by 43 companies.
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Acute Myeloid Leukemia Research
- 38 registered trials on ClinicalTrials.gov
- Open Payments reporting from 43 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 228 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 808.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 38 registered studies on ClinicalTrials.gov. The most recent:
- A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 27 Aug 2026
43 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202534 payments$51,949openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20254 payments$27,110openpaymentsdata.cms.gov ↗
- Hikma Pharmaceuticals USAProgram year20259 payments$23,787openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
64.3%Fluoroquinolone Antibacterial32.1%Levofloxacin100%Part D≥14 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor32.1%Valacyclovir100%Part D≥13 patientsCancer & immunology
35.7%BCL-2 Inhibitor35.7%Venclexta100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.
American journal of hematology
Letter2026 - Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.
Blood cancer journal
Review2026 - Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
Blood cancer journal
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04Ibrutinib and Venetoclax for First-Line Treatment of CLL504 citations2019
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/lab/Elias-Jabbour-Lab
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/scientific-contributions/Elias-J-Jabbour-2145453855
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/blood-cancers-today_elias-jabbour-md-recognizes-blood-cancer-activity-6977735433006850048-NqKJ
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/societyofhematologiconcology_elias-jabbour-md-talks-about-obe-cel-ash-activity-7279908134733692928-eUz0
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
bloodcancerstoday.com/author/elias-jabbour-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Board Certified
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Board Certified
American Board of Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nature.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →karger.com ↗
- Editorial Board Member
Blood Advances -- claimed on MD Anderson bio but NOT found on ASH Publications' own official Blood Advances editorial board listing after 3 verification attempts …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
- King Hussein Cancer Award for Cancer Research
Lifetime Achievement (International Physician category)
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kinghusseincanceraward.jo ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniusj.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Media & interviews
press, podcasts and appearances- OncLive On Air podcast/video series -- multiple appearances discussing CML
ALL, olverembatinib, ponatinib (recurring contributor)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center